Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

VIVUS Inc. (VVUS - Snapshot Report) recently announced that the European Commission (EC) has cleared its drug, Spedra, phosphodiesterase type 5 (PDE5) inhibitor, for the treatment of erectile dysfunction (ED) in the EU. The approval did not come as a surprise as, in Apr 2013, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of the drug.

The approval came on the basis of promising data from three phase III trials REVIVE, REVIVE-Diabetes and REVIVE-RP and a year-long safety study. Investors reacted positively to the news.

We note that the US Food and Drug Administration (FDA) approved the drug under the trade name Stendra for ED in April last year. VIVUS is looking for partners in the US and EU to market the drug.

We note that a few days back VIVUS announced encouraging data from a multi-center, placebo-controlled study (TA-501) evaluating the efficacy of Stendra in men suffering from ED.

The study enrolled 440 patients with mild-to-severe ED with or without diabetes. Data from the study revealed that on an average Stendra was effective after 10 minutes and 12 minutes of taking the 200 mg and 100 mg formulation of the drug, respectively.

According to the company, ED therapies recorded combined sales of over $5.5 billion in 2012. The ED market is expected to grow further in the coming years.

Currently approved PDE5 inhibitors including Pfizer Inc.’s (PFE - Analyst Report) Viagra and Eli Lilly and Company’s (LLY - Analyst Report) Cialis are recommended for ingestion one to two hours prior to sexual activity or daily. We believe Stendra’s fast action could help the drug gain share once launched. Additionally, it will also help VIVUS to secure a lucrative partnership deal for Stendra in the US and EU.

VIVUS, currently carries a Zacks Rank #3 (Hold). Companies that currently look attractive include Salix Pharmaceuticals (SLXP - Analyst Report) with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%